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Problem/Background

• American Diabetes Association guidelines for inpatient
management recommend blood glucose between 100-180
mg/dL for non-critically ill hospitalized patients.
• Adequate glycemic control is an important aspect of overall
cancer treatment outcomes. Uncontrolled glucose levels in
inpatients can cause adverse outcomes.
• The use of a sliding scale (SSI) only insulin regimen is one of
the common reasons for hyperglycemia in the hospitals, but
Basal bolus Insulin (BBI) therapy is found to be more
effective.

•

•

Intervention

Implementation of Insulin decision support (IDS) tool, based on the
institutional hyperglycemia algorithm, to guide providers to place BBI
orders. The IDS tool would allow providers to identify patients needing
insulin, determine the total daily dose of insulin taking into
consideration of patient’s weight, nutritional status, steroid use, and
kidney function etc., and divide the total daily dose into basal, bolus and
correctional parts and then link to actual insulin orders.
Education of Hospital Medicine providers, and weekly e-mail reminders.

Data Analysis

• As per the baseline data more than 66 % of diabetes patients
with blood glucose >200 mg/dL are being placed on the SSI
regimen in the Hospital Medicine unit.
• Providers rely on SSI rather than BBI due to knowledge
deficit , fear of causing hypoglycemia, lack of best practice
protocols/ guidelines, or structured order sets.

Purpose/Goal

• Increase the use of Basal Bolus Insulin therapy within 48
hours of blood sugar more than 200 mg/dL, in non-critically
ill diabetes patients admitted to the Hospital Medicine unit
of MD Anderson Cancer Center by 40% from baseline by
October 2021.

Methods

• Design : QI project, Pre-post intervention group design.
• Setting : Single inpatient unit, (Hospital Medicine unit)
within a large comprehensive Cancer Center in USA.
• Sample/Inclusion criteria : Non critically ill diabetes patients
with blood glucose levels >200mg/dL (ICD codes used to
filter the data E11* (type 2 diabetes), OR E09* OR E13* (the
star captures all the sub codes underneath).
• Exclusion criteria : Type 1 diabetes, pediatric patients , ICU
status patients, patients with Covid 19 diagnosis, patients on
insulin pump, tube feed or TPN.
• Preliminary post intervention data (weekly from December
1, 2020, to February 8, 2021)
Pre-intervention data from January 1, 2019 – March 31, 2019

Preliminary Data

• The implementation of IDS tool, which is integrated in the Epic,
can assist providers in placing appropriate BBI insulin orders.
• Increased use of BBI use can result in reduction in hyperglycemia
and hypoglycemia which can enhances overall patient safety and
outcomes.
• Expanding or standardizing the intervention to other areas can
help change prescriber practice and better glycemic control.
•
• Provider involvement and interest is an important factor in the
utilization of the IDS tool.

Looking Ahead

• Continue to identify barriers in using the IDS tool and provide
education and support.
• Make necessary changes to the IDS tool based on provider
feedback.
• Reanalyze data for a longer period to see the trend in the of BBI
use.
• Expand the intervention to other primary care units at MD
Anderson
• Aim for further increase of BBI use to 70-80%.
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